Selected research
Market Structure
Global Emphysema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Emphysema Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Emphysema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Emphysema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Emphysema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Emphysema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Emphysema Drug include Angion Biomedica Corp., ProMetic Life Sciences Inc., rEVO Biologics, Inc., SATT North SAS and TGV-Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Emphysema Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Emphysema Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Emphysema Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Emphysema Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Emphysema Drug Segment by Company
Angion Biomedica Corp.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
SATT North SAS
TGV-Laboratories
Emphysema Drug Segment by Type
MG-53
EDO-66
BB-3
Others
Emphysema Drug Segment by Application
Hospital
Clinic
Others
Emphysema Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Emphysema Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Emphysema Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Emphysema Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Emphysema Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Emphysema Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Emphysema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Emphysema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- MG-53
- EDO-66
- BB-3
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Angion Biomedica Corp.
- ProMetic Life Sciences Inc.
- rEVO Biologics, Inc.
- SATT North SAS
- TGV-Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Emphysema Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Emphysema Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Emphysema Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Emphysema Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Emphysema Drug Market Dynamics
- 2.1 Emphysema Drug Industry Trends
- 2.2 Emphysema Drug Industry Drivers
- 2.3 Emphysema Drug Industry Opportunities and Challenges
- 2.4 Emphysema Drug Industry Restraints
3 Emphysema Drug Market by Manufacturers
- 3.1 Global Emphysema Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Emphysema Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Emphysema Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Emphysema Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Emphysema Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Emphysema Drug Manufacturers, Product Type & Application
- 3.7 Global Emphysema Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Emphysema Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Emphysema Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Emphysema Drug Tier 1, Tier 2, and Tier 3
4 Emphysema Drug Market by Type
- 4.1 Emphysema Drug Type Introduction
- 4.1.1 MG-53
- 4.1.2 EDO-66
- 4.1.3 BB-3
- 4.1.4 Others
- 4.2 Global Emphysema Drug Sales by Type
- 4.2.1 Global Emphysema Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Emphysema Drug Sales by Type (2021-2032)
- 4.2.3 Global Emphysema Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Emphysema Drug Revenue by Type
- 4.3.1 Global Emphysema Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Emphysema Drug Revenue by Type (2021-2032)
- 4.3.3 Global Emphysema Drug Revenue Market Share by Type (2021-2032)
5 Emphysema Drug Market by Application
- 5.1 Emphysema Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Emphysema Drug Sales by Application
- 5.2.1 Global Emphysema Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Emphysema Drug Sales by Application (2021-2032)
- 5.2.3 Global Emphysema Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Emphysema Drug Revenue by Application
- 5.3.1 Global Emphysema Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Emphysema Drug Revenue by Application (2021-2032)
- 5.3.3 Global Emphysema Drug Revenue Market Share by Application (2021-2032)
6 Global Emphysema Drug Sales by Region
- 6.1 Global Emphysema Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Emphysema Drug Sales by Region (2021-2032)
- 6.2.1 Global Emphysema Drug Sales by Region (2021-2026)
- 6.2.2 Global Emphysema Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Emphysema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Emphysema Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Emphysema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Emphysema Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Emphysema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Emphysema Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Emphysema Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Emphysema Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Emphysema Drug Revenue by Region
- 7.1 Global Emphysema Drug Revenue by Region
- 7.1.1 Global Emphysema Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Emphysema Drug Revenue by Region (2021-2026)
- 7.1.3 Global Emphysema Drug Revenue by Region (2027-2032)
- 7.1.4 Global Emphysema Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Emphysema Drug Revenue (2021-2032)
- 7.2.2 North America Emphysema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Emphysema Drug Revenue (2021-2032)
- 7.3.2 Europe Emphysema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Emphysema Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Emphysema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Emphysema Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Emphysema Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Angion Biomedica Corp.
- 8.1.1 Angion Biomedica Corp. Company Information
- 8.1.2 Angion Biomedica Corp. Business Overview
- 8.1.3 Angion Biomedica Corp. Emphysema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Angion Biomedica Corp. Emphysema Drug Product Portfolio
- 8.1.5 Angion Biomedica Corp. Recent Developments
- 8.2 ProMetic Life Sciences Inc.
- 8.2.1 ProMetic Life Sciences Inc. Company Information
- 8.2.2 ProMetic Life Sciences Inc. Business Overview
- 8.2.3 ProMetic Life Sciences Inc. Emphysema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 ProMetic Life Sciences Inc. Emphysema Drug Product Portfolio
- 8.2.5 ProMetic Life Sciences Inc. Recent Developments
- 8.3 rEVO Biologics, Inc.
- 8.3.1 rEVO Biologics, Inc. Company Information
- 8.3.2 rEVO Biologics, Inc. Business Overview
- 8.3.3 rEVO Biologics, Inc. Emphysema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 rEVO Biologics, Inc. Emphysema Drug Product Portfolio
- 8.3.5 rEVO Biologics, Inc. Recent Developments
- 8.4 SATT North SAS
- 8.4.1 SATT North SAS Company Information
- 8.4.2 SATT North SAS Business Overview
- 8.4.3 SATT North SAS Emphysema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 SATT North SAS Emphysema Drug Product Portfolio
- 8.4.5 SATT North SAS Recent Developments
- 8.5 TGV-Laboratories
- 8.5.1 TGV-Laboratories Company Information
- 8.5.2 TGV-Laboratories Business Overview
- 8.5.3 TGV-Laboratories Emphysema Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 TGV-Laboratories Emphysema Drug Product Portfolio
- 8.5.5 TGV-Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Emphysema Drug Value Chain Analysis
- 9.1.1 Emphysema Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Emphysema Drug Production Mode & Process
- 9.2 Emphysema Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Emphysema Drug Distributors
- 9.2.3 Emphysema Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst